Zim Laboratories Limited (ZIMLAB) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Zim Laboratories Limited stock ₹19.02, price ₹140, that is 86.4% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Zim Laboratories Limited
ZIMLAB · NSEFar too expensive (fair value 86% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
48‑month range ₹60.26 – ₹152.63 · fair‑value band ₹13.31 – ₹24.72 · the ₹139.87 price screens above the ₹19.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Zim Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally.
Show moreShow less
It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films.
The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.
Stock analysis
Zim Laboratories Limited (ZIMLAB) currently trades at ₹139.87, while our model-based Fair Value estimate is ₹19.02, 86% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹36.07 per share, and 1 of the 13 models we run sit above the ₹139.87 price.
Bear case: the Earnings-Based group reads lowest at ₹3.95, and 12 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹13.31 (bear) to ₹24.72 (bull), the price of ₹139.87 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Zim Laboratories Limited reported revenue of ₹3.7B in FY2026 versus ₹3.3B in FY2022, a compound +2.8%/yr. Reported net income was ₹58.4M in FY2026, compounding −20.4%/yr from FY2022.
Key figures
Market cap ₹6.9B (≈ $72.8M) Micro · P/E ratio 170.6 · P/S ratio 1.74 · EPS (TTM) ₹0.8200 · Net margin 0.9% · Return on equity 2.1% · Return on assets (EBIT) 9.1% (5-year average) · Operating margin −3.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 132% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −86%, ZIMLAB screens richer than that median.
Fair Value models
All 14 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
ZIMLAB screens overvalued: fair value 86% below the price. Compare with Merck KGaA →
Compare Zim Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs ZIMLAB |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs ZIMLAB |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs ZIMLAB |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs ZIMLAB |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs ZIMLAB |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs ZIMLAB |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs ZIMLAB |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs ZIMLAB |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs ZIMLAB |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs ZIMLAB |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Zim Laboratories Limited (ZIMLAB) overvalued or undervalued?
What is the fair value of ZIMLAB?
What is the quality score of ZIMLAB?
What is the price target for Zim Laboratories Limited (ZIMLAB)?
What is the Zim Laboratories Limited stock forecast for 2026?
What is the revenue of Zim Laboratories Limited (ZIMLAB)?
What is the intrinsic value of Zim Laboratories Limited (ZIMLAB)?
Is Zim Laboratories Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ZIMLAB?
How much is Zim Laboratories Limited worth?
What do the bullish and bearish scenarios say about ZIMLAB?
What is the P/E ratio of ZIMLAB?
How solid is the balance sheet of Zim Laboratories Limited (ZIMLAB)?
How far is ZIMLAB from its 52-week high?
Which stocks are comparable to Zim Laboratories Limited?
Is Zim Laboratories Limited stock attractive at the current price?
How is the fair value of ZIMLAB calculated?
Is it still worth investing in stocks now?
What is the share price of Zim Laboratories Limited (ZIMLAB)?
What should I pay attention to with Zim Laboratories Limited right now?
Where does the earnings growth of Zim Laboratories Limited (ZIMLAB) come from?
Key figures of Zim Laboratories Limited
How large is the market capitalisation of Zim Laboratories Limited (ZIMLAB)?
What is the P/S ratio of Zim Laboratories Limited (ZIMLAB)?
What are the earnings per share of Zim Laboratories Limited (ZIMLAB)?
What is the net margin of Zim Laboratories Limited (ZIMLAB)?
What is the return on equity of Zim Laboratories Limited (ZIMLAB)?
What is the EBIT return on assets of Zim Laboratories Limited (ZIMLAB)?
What is the operating margin of Zim Laboratories Limited (ZIMLAB)?
How fast is revenue growing at Zim Laboratories Limited (ZIMLAB)?
How fast are earnings growing at Zim Laboratories Limited (ZIMLAB)?
How much free cash flow does Zim Laboratories Limited (ZIMLAB) generate?
How much net debt does Zim Laboratories Limited (ZIMLAB) carry?
Watch Zim Laboratories Limited in the live analysis
One click puts Zim Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.